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Background. Facial angiofibromas affect most patients with tuberous sclerosis complex. They tend to progress, can cause recurrent
bleeding and facial disfigurement, and have significant psychological effects. We reviewed the effectiveness and safety of topical
sirolimus ointment 0.1%. We also assessed the effect of treatment on quality of life. Methods. We report our experience in using
sirolimus ointment in 14 patients with TSC (9 children and 5 adults). The impact of sirolimus ointment was monitored with digital
photography, dermatological review using a validated Facial Angiofibroma Severity Index (FASI), and quality of life assessments
using the questionnaires PedsQL for children and SF36 for adults. Results. The FASI scores were improved in 12/14 cases after six
months’ treatment, and improvement was more likely in children (median FASI scores of improvement after treatment were 3
points for children and 1 for adults). Proxy-reported PedsQL scores for the total psychosocial domain improved significantly in the
children in the cohort with treatment. Conclusions. Sirolimus ointment 0.1% administered once a day was effective in treating facial
angiofibromas. It appears to be safe and well tolerated and to have a positive impact on patients’ quality of life. It appeared to be
most beneficial when started in childhood.
1. Introduction
Tuberous sclerosis complex (TSC) is a neurocutaneous con-
dition which has an autosomal dominant pattern of inher-
itance. Approximately two-thirds of cases are sporadic. The
birth incidence has been estimated as 1 in 5,800 per year [1].
This condition is caused by mutations in the tumour
suppressor genes TSC1 and TSC2. TSC1 encodes for the pro-
tein hamartin which is located on chromosome 9, and TSC2
encodes for the protein tuberin, located on chromosome 16
[2, 3]. Hamartin and tuberin function together within the cell
as a complex and have an inhibitory effect on themammalian
Target Of Rapamycin (mTOR), a protein kinase that affects
cell growth and division through the regulation of protein
synthesis [4, 5]. Mutation in either TSC1 or TSC2 genes
leads to overactivation of mTOR pathway, which will lead
to uncontrolled cell growth. This, in turn, causes growth of
benign tumours (hamartomas) inmultiple organs such as the
brain, kidneys, skin, heart, and lungs, which are the clinical
hallmarks of the disease.
Approximately 86% of patients with TSC suffer from
facial angiofibromas, which are benign tumours on the face.
They generally become noticeable at around the age of
five years. The severity varies significantly between patients.
They can have a huge impact on a patient’s self-esteem [6].
In addition, they are known to cause recurrent bleeding,
irritation, infection, facial scarring, and disfigurement [7].
The mTOR inhibitors mimic the action of the TSC gene
products, by inhibiting the action ofmTORand therefore reg-
ulating the PI3 kinase-mTOR-S6 kinase intracellular growth
pathway. Sirolimus (also known as rapamycin) and its 40-
O-(2-hydroxyethyl) derivative, everolimus, effectively inhibit
mTOR [8–10]. In recent years, systemic mTOR inhibitors
have been used to treat the complications of TSC and it
has been shown that they shrink TSC lesions such as renal
angiomyolipomas and subependymal giant cell astrocytomas
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and that they improve facial angiofibromas [11, 12]. However,
their use is constrained by concerns about systemic side
effects. There have been several case reports of sirolimus
ointment for the treatment of facial angiofibromas, where dif-
ferent sirolimus ointment strength, preparation, and regimes
have been used. None of these studies have used a validated
tool to assess the severity of the rash and its response to
treatment [13].
The best-established treatment options to date for facial
angiofibromas are laser therapy and surgical removal of the
large lesions. However, many patients also have learning
difficulties and do not tolerate the sessions of laser therapy
without multiple general anaesthetics. We report our experi-
ence in using sirolimus ointment 0.1% for facial angiofibro-
mas in children and adults with TSC, using a standardised
and validated Facial Angiofibroma Severity Index. We also
assessed the effect of this treatment on quality of life.
2. Materials and Methods
Fourteen sequential patients with a definite diagnosis of TSC,
as defined by the International Tuberous Sclerosis Complex
Consensus Group [14], from our TS clinic at the Royal
United Hospital in Bath started using sirolimus ointment
from May 2014. Any patients who were suitable were offered
the treatment.Wehad 14 patients suitable for this treatment at
the time. We did not exclude any patients. Any patients who
attended the clinic in May 2014 and had facial angiofibromas
agreed to try sirolimus ointment. None of the patients were
on systemic mTOR inhibitors before starting or during this
treatment of topical sirolimus.
The gender balance and prevalence of learning disabilities
in our clinic cohort are similar to previously reported popula-
tion based TSC cohorts, suggesting that this clinic population
is not grossly dissimilar from the TSC population at large [15]
Topical 0.1% sirolimus ointment was used. The patients
were advised to apply a thin coating to the affected areas
on the face, once a day in the evening. Each ointment pot
contained 30mg of sirolimus in 30 grams of ointment, and
this consisted of 15 tablets of sirolimus (rapamycin 2mg
tablets) crushed and mixed with white soft paraffin.
One pot was given for 6 weeks. Each pot costed approx-
imately m180. The treatment was not funded by any pharma-
ceutical companies. The cost was covered by the NHS as this
treatment was part of patient’s standard care. An information
leaflet about topical sirolimus therapy was given to our
patients at the start of the therapy. Patientswere advised to use
hydrocortisone cream should they suffer from irritation or a
burning sensation. We routinely use digital photography to
monitor the effectiveness of topical sirolimus in our patients.
Digital photography was undertaken at baseline, and then at
six months. Six photographs were taken by a digital camera
from each patient at each visit.Three photographs were taken
with the camera flash on and the other three are taken with
the flash in automatic mode. One photograph was taken in
full face view directly facing the camera and the other two
were side profiles.The preferred facial expression was natural
with both eyes open. However, a facial smile was acceptable.
Patients were advised not to wearmakeup before having their
photo taken. None of the patients in this series wore make up
during the visits.
During each visit, patients, parents, and carers were
asked to report on the degree of improvement. The treating
physicians were also reporting the effect of the ointment.
In order to obtain a more objective assessment of the treat-
ment our consultant dermatologist analysed the photographs
and scored treatment response in a blinded fashion. The
dermatologist was given the pre- and posttreatment photos
for each patient without knowing whether they were pre-
or posttreatment photos. The Facial Angiofibroma Severity
Index (FASI) was used by the dermatologist to assess the
severity of the rash.
The FASI is an objective clinical tool that assesses the
severity of facial angiofibromas and treatment response. The
index has good interrater reliability (correlation coefficient
𝑠 > 0.98; range 0.97–0.99) [16]. The score is obtained by
summing the partial scores assigned to each of three features:
erythema, size, and extent of lesions. Erythema and lesion
size are scored from 0 to 3, while the extent is scored 2 to 3.
Mild, moderate, and severe facial angiofibroma correspond
with activity score ranges on the FASI of ≤5, 6-7, and ≥8,
respectively (Table 1).
We use the Pediatric Quality of Life Inventory (PedsQL)
in our clinic to monitor children’s quality of life. PedsQL
is a reliable and valid assessment tool for quality of life in
children. It is also concise, has age appropriate versions,
and has parallel forms for children and parents [17]. For
the adult patients, we use the Short Form 36 Health Survey
Questionnaire (SF-36) to assess the quality of life [18].
FASI scores pre- and posttreatment were compared using
Wilcoxon signed-rank sum test. Mann–Whitney U Test was
used to compare the FASI scores between children and adults.
Quality of life scores were compared using Student’s paired
t-test. Ethical approval was not required as this treatment
is being used as part of patient’s routine care. This is not a
clinical trial. This treatment was available to all patients who
were suitable. Consent was taken from each patient for taking
facial photographs.
3. Results
3.1. Patient Characteristics. Fourteen patients (9 children and
5 adults; 7 male) were in this cohort. The median age was 16
and the range was from 9 to 40 years. Five cases had learning
difficulties. Six cases had already received laser therapy
or surgery for their facial rash in the past but significant
angiofibromatosis remained. None of these patients received
laser therapy or surgery in the 6 months prior to starting
or during the topical treatment. None of the patients in this
group had received topical mTOR inhibitors before starting
the topical sirolimus therapy and none of them had received
systemic mTOR inhibitors before or during the course of the
study. Before the treatment, 4 patients had the maximum
FASI score of 9, 7 patients scored 8, and 3 had a FASI score
of 7 (Table 1).
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1 12 C Yes 2 3 3 8 0 2 3 5
2 11 D No 2 3 3 8 1 2 2 5
3 13 D No 2 3 3 8 0 1 3 4
4 14 C No 2 3 3 8 1 2 3 6
5 16 D No 2 2 3 7 0 1 2 3
6 9 C No 2 3 3 8 1 2 3 6
7 17 C No 2 3 3 8 1 2 3 6
8 14 C Yes 2 2 3 7 1 2 2 5
9 9 D Yes 3 3 3 9 2 2 2 6
10 23 D No 3 3 3 9 3 3 3 9
11 27 D No 3 3 3 9 3 3 3 9
12 24 C No 2 3 3 8 1 2 3 6
13 22 D Yes 3 3 3 9 2 3 3 8
14 40 C Yes 1 3 3 7 0 3 3 6
Erythema. Skin color: 0, light red: 1, red: 2, and dark red/purple: 3. Size. Small (<5mm): 1, large (>5mm): 2, and confluent: 3. Extension. <50% cheek area: 2
and >50% cheek area: 3. FASI Score. < or = 5: mild, 6-7: moderate, and = or >8: severe.
3.2. Treatment Response. Based on the FASI photographic
assessments by our dermatologist, FASI scoreswere improved
in twelve out of fourteen (Figures 1 and 4 andTable 1) (2-tailed
Wilcoxon signed-rank test 𝑝 = 0.002). Of the remaining 2
patients, 1 had improvement in rash but no FASI score change.
One had no detectable response. The treating physicians
reported improvement in 13 out of 14 patients. Thirteen out
of fourteen patients and their parents or carers reported facial
angiofibroma improvement.
No one had worsening of facial angiofibromas after the
therapy. Children (age 0–16 years) in this cohort responded
better to the treatment than the adults. Median FASI scores
improvement after treatment were three points for children
and one point for adults (Mann–Whitney U Test 𝑝 =
0.053). All the children had an improvement in their facial
angiofibromas after 6 months compared with four out of five
adults. The presence of learning disabilities had no apparent
relationship with response to treatment. The median FASI
scores improvement after treatment were 2 points for both
patients with and without learning disabilities. Both female
and male patients were equally responsive to this treatment.
3.3. Quality of Life. PedsQL was used in nine patients to
assess their quality of life. Six children had no learning
difficulties and completed the self-reported PedsQL. The
self-reported scores for total psychosocial domain improved
in five out of six patients (Figure 2(a)). The parents of all
the nine paediatric patients completed the proxy PedsQL.
The proxy-reported scores for total psychosocial domain
improved significantly after treatment (paired 𝑡-test: 𝑡 =
−3.09, 𝑝 = 0.014), with individual scores improving in five
patients, staying the same in two and marginally declining in
two (Figure 2(b)).
Four adult patients had their quality of life assessed using
SF36. The vitality/energy domain scores of SF36 improved
markedly in two patients and stayed the same in two (Fig-
ure 3(a)). The social functioning domain scores improved in
three patients and declined in one (Figure 3(b)).
For the patient who had an unchanged FASI score but still
reported rash improvement and also reported improvements
in quality of life, his social function domain scores improved
from 50 to 100 and vitality/energy from 56 to 69. The patient
who had neither FASI nor facial angiofibroma improvement
also had no improvement in quality of life.
3.4. Adverse Reactions. One patient developed facial redness
two weeks after commencing the treatment. Hydrocortisone
cream was used successfully to treat the reaction. He contin-
ued with sirolimus ointment and had no further reaction. No
other patients reported any adverse events.
4. Discussion
This report shows that the facial angiofibromas, assessed
by a dermatology assessment of photographs, using FASI,
showed improvement in 12/14 TSC cases after 6 months
of sirolimus ointment 0.1% treatment. The strength of this
study is that it has attempted to objectively assess response
of facial angiofibromatosis to topical mTOR inhibition using
a validated instrument and an assessor blinded to treatment
status. It has also attempted to describe the impact of
treatment on the quality of life of patients. Sirolimus ointment
and cream have been used in smaller case series. However,
none of these reports have been from the UK and none
have objectively assessed effectiveness and/or quality of life
[19, 20].
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(a) Showing self-report responses by the children to the PedsQL





























(b) Showing proxy-report responses by the parents of all the children to


















































(b) Showing SF36 social functioning scores for the adult patients before
and after the treatment
Figure 3
One of the patients who did not show FASI score
improvement had a very severe rash before treatment and it
remained very severe after treatment. His rash had improved
but not enough to change the FASI score. It may be that the
FASI score is not sensitive enough to pick up improvement
in patients with very severe rash. In particular, this patient’s
rash was less erythematous after treatment. Erythema is an
important component of facial angiofibromatosis and it is the
component that demonstrated the greatest improvement in
the FASI scores. The degree of erythema noticed on visual
inspection is reliably correlated with blood flow detected by
Doppler scans [21]. It is probable that the topical mTOR
































Figure 4: Showing FASI scores before and after treatment.
inhibitor has been especially successful in reducing the
vascularity of the angiofibromatosis. It is known that systemic
mTOR inhibitors have a potent effect on the vascularity of
other TSC lesions such as renal angiomyolipomas.
The better response amongst children compared to adults
with this treatment is possibly due to the fact that the
children’s rash was less severe before the treatment compared
with the adults or because the rash is still developing and
therefore is more susceptible to intervention. We know from
clinical experience that facial angiofibromas tend to stabilise
in adulthood.The median FASI scores for children improved
from 8 to 5.5 while for adults the scores were from 9 to 8.
These results suggest that early intervention may be more
effective and therefore justifiable.
The treatment has improved the quality of life of the
children and adults in this study. The treatment specifically
showed a significant impact on the psychosocial domain
component of the quality of life scores. The psychological
impact of facial angiofibromas onTSCpatientsmay be under-
appreciated by healthcare professionals. In our experience,
a lot of young children with TSC, who are mildly affected
by the facial rash, still get teased or picked on at school
by their peers. This can have a significant bearing on their
school progress, which can also be associated with numerous
physical,mental, and social harms [22].Thephysical domains
of quality of life were also assessed as they are part of the
PedsQL and SF36 questionnaires. However, there was no
difference in the physical domains before and after treatment
in these patients. The parents and carers of one adult patient
in this study have not completed an SF36 form on behalf of
the patient as they found the questions difficult to answer.
SF36 is a reliable tool and has content validity [18]. However,
it may not be so reliable for adults with learning difficulties.
There is no standardised and validated tool for quality of life
assessment in adults with severe learning difficulties.
There are limitations with this case series report. Firstly,
this is not a randomised placebo controlled trial and therefore
the results may be subject to bias and there is certainly likely
to be a lack of power in any statistical analyses. Secondly, we
have not systematically measured compliance to treatment
and therefore we cannot say that lack of response to treatment
is not due to lack of compliance. However, it is reasonable
to suggest that the improvement in facial angiofibromato-
sis demonstrated in this series is likely to be due to the
topical treatment because we know from clinical experience
that facial angiofibromas generally do not improve without
intervention. Another limitation to the study is that the
quality of life questionnaires for patients with severe learning
difficulties was completed by parents and carers.Thismethod
of quality of life assessment is less reliable than self-reported
outcome, but it is the only practicable method of assessment
in people with learning disability, and it remains of interest. It
is possible that the improvementwe have seen in quality of life
is due to a placebo effect or close follow-up. However, there
is good correlation between response of rash to treatment
and improvement in quality of life. All the patients who had
facial angiofibroma improvement also had improvement in
quality of life. In addition, we have seen more improvement
in psychosocial domains rather than physical domains after
the treatment.
All of the patients treated with this ointment have
requested to continue the treatment and this high retention
rate further suggests that it is an effective intervention with
limited inconvenience or adverse effects. It will be interesting
to see whether long-term treatment results in continued
improvement. We do know from clinical experience that
stopping treatment results in recurrence. We will continue
to review them regularly as this treatment constitutes part of
their ongoing clinical care. Unfortunately, not many patients
in the UK have access to this ointment due to funding.We are
hoping that reporting our experience of sirolimus ointment
use will support family groups in streamlining funding for
this treatment.
5. Conclusion
Sirolimus ointment 0.1% once a day was apparently effective
in treating facial angiofibromas in our clinical cohort. It also
appeared to be safe and well tolerated and had a positive
significant impact on patients’ quality of life. We saw greater
effect in children than adults and therefore early treatment
may be advisable. The positive outcomes from this case
series suggest that a larger prospective placebo controlled
randomised controlled trial is justified.The safety and efficacy
of 0.1% sirolimus in this group set a baseline platform for a
larger national study to compare 0.1% strength with a higher
strength and placebo. There is a need for a national study
to determine optimal dosing regimen of topical sirolimus
for facial angiofibromas in TSC, to facilitate EMA licence
application for this indication, and to facilitate NHS funding
for this treatment. Currently, this treatment is not available
through the NHS in all the Tuberous Sclerosis Clinics in the
United Kingdom.
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